125 related articles for article (PubMed ID: 38918871)
1. S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis.
Brunner HI; Schulert GS; Sproles A; Thornton S; Cornejo GV; Antón J; Cuttica R; Henrickson M; Foeldvari I; Kingsbury DJ; Askelson M; Liu J; Mukherjee S; Wong RL; Lovell DJ; Martini A; Ruperto N; Grom AA;
Arthritis Res Ther; 2024 Jun; 26(1):125. PubMed ID: 38918871
[TBL] [Abstract][Full Text] [Related]
2. Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy.
Hinze CH; Foell D; Johnson AL; Spalding SJ; Gottlieb BS; Morris PW; Kimura Y; Onel K; Li SC; Grom AA; Taylor J; Brunner HI; Huggins JL; Nocton JJ; Haines KA; Edelheit BS; Shishov M; Jung LK; Williams CB; Tesher MS; Costanzo DM; Zemel LS; Dare JA; Passo MH; Ede KC; Olson JC; Cassidy EA; Griffin TA; Wagner-Weiner L; Weiss JE; Vogler LB; Rouster-Stevens KA; Beukelman T; Cron RQ; Kietz D; Schikler K; Mehta J; Ting TV; Verbsky JW; Eberhard AB; Huang B; Giannini EH; Lovell DJ
Arthritis Rheumatol; 2019 Mar; 71(3):451-459. PubMed ID: 30225949
[TBL] [Abstract][Full Text] [Related]
3. Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study.
Hara R; Umebayashi H; Takei S; Okamoto N; Iwata N; Yamasaki Y; Nakagishi Y; Kizawa T; Kobayashi I; Imagawa T; Kinjo N; Amano N; Takahashi Y; Mori M; Itoh Y; Yokota S
Pediatr Rheumatol Online J; 2019 Apr; 17(1):17. PubMed ID: 31039807
[TBL] [Abstract][Full Text] [Related]
4. Model-Based Selection and Recommendation for Subcutaneous Abatacept Dose in Patients With Polyarticular Juvenile Idiopathic Arthritis.
Gandhi Y; Passarell JA; Roy A; Murthy B
J Clin Pharmacol; 2021 May; 61(5):688-699. PubMed ID: 33284480
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study.
Brunner HI; Tzaribachev N; Vega-Cornejo G; Louw I; Berman A; Calvo Penadés I; Antón J; Ávila-Zapata F; Cuttica R; Horneff G; Foeldvari I; Keltsev V; Kingsbury DJ; Viola DO; Joos R; Lauwerys B; Paz Gastañaga ME; Rama ME; Wouters C; Bohnsack J; Breedt J; Fischbach M; Lutz T; Minden K; Miraval T; Ally MMTM; Rubio-Pérez N; Solau Gervais E; van Zyl R; Li X; Nys M; Wong R; Banerjee S; Lovell DJ; Martini A; Ruperto N;
Arthritis Rheumatol; 2018 Jul; 70(7):1144-1154. PubMed ID: 29481737
[TBL] [Abstract][Full Text] [Related]
6. S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis.
Gohar F; Anink J; Moncrieffe H; Van Suijlekom-Smit LWA; Prince FHM; van Rossum MAJ; Dolman KM; Hoppenreijs EPAH; Ten Cate R; Ursu S; Wedderburn LR; Horneff G; Frosch M; Foell D; Holzinger D
J Rheumatol; 2018 Apr; 45(4):547-554. PubMed ID: 29335345
[TBL] [Abstract][Full Text] [Related]
7. The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis.
Aljaberi N; Tronconi E; Schulert G; Grom AA; Lovell DJ; Huggins JL; Henrickson M; Brunner HI
Pediatr Rheumatol Online J; 2020 Jan; 18(1):7. PubMed ID: 31948488
[TBL] [Abstract][Full Text] [Related]
8. Elevated S100A8/A9 and S100A12 Serum Levels Reflect Intraocular Inflammation in Juvenile Idiopathic Arthritis-Associated Uveitis: Results From a Pilot Study.
Walscheid K; Heiligenhaus A; Holzinger D; Roth J; Heinz C; Tappeiner C; Kasper M; Foell D
Invest Ophthalmol Vis Sci; 2015 Dec; 56(13):7653-60. PubMed ID: 26624497
[TBL] [Abstract][Full Text] [Related]
9. Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis.
Brunner HI; Wong R; Nys M; Kou TD; Dominique A; Martini A; Lovell DJ; Ruperto N;
Paediatr Drugs; 2020 Dec; 22(6):653-672. PubMed ID: 33029724
[TBL] [Abstract][Full Text] [Related]
10. Abatacept as Monotherapy and in Combination With Methotrexate in Patients With Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials.
Ruperto N; Lovell DJ; Berman A; Anton J; Viola DO; Lauwerys B; Rama ME; Bohnsack J; Breedt J; Fischbach M; Lutz T; Minden K; Ally M; Rubio-Pérez N; Gervais E; Van Zyl R; Wong R; Askelson M; Martini A; Brunner HI;
J Rheumatol; 2023 Nov; 50(11):1471-1480. PubMed ID: 37453737
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate.
Lovell DJ; Brunner HI; Reiff AO; Jung L; Jarosova K; Němcová D; Mouy R; Sandborg C; Bohnsack JF; Elewaut D; Gabriel C; Higgins G; Kone-Paut I; Jones OY; Vargová V; Chalom E; Wouters C; Lagunes I; Song Y; Martini A; Ruperto N
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665432
[TBL] [Abstract][Full Text] [Related]
12. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
13. Trajectories of disease courses in the inception cohort of newly diagnosed patients with JIA (ICON-JIA): the potential of serum biomarkers at baseline.
Ganeva M; Fuehner S; Kessel C; Klotsche J; Niewerth M; Minden K; Foell D; Hinze CH; Wittkowski H
Pediatr Rheumatol Online J; 2021 May; 19(1):64. PubMed ID: 33933108
[TBL] [Abstract][Full Text] [Related]
14. Low pretreatment levels of myeloid-related protein-8/14 and C-reactive protein predict poor adherence to treatment with tumor necrosis factor inhibitors in juvenile idiopathic arthritis.
Alberdi-Saugstrup M; Nielsen S; Mathiessen P; Nielsen CH; Müller K
Clin Rheumatol; 2017 Jan; 36(1):67-75. PubMed ID: 27562034
[TBL] [Abstract][Full Text] [Related]
15. Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis.
Rothmund F; Gerss J; Ruperto N; Däbritz J; Wittkowski H; Frosch M; Wulffraat NM; Wedderburn LR; Holzinger D; Gohar F; Vastert SJ; Brik R; Deslandre CJ; Melo-Gomes JA; Saad Magalhaes C; Barcellona R; Russo R; Gattorno M; Martini A; Roth J; Foell D;
Arthritis Care Res (Hoboken); 2014 Jun; 66(6):949-55. PubMed ID: 24339418
[TBL] [Abstract][Full Text] [Related]
16. Prediction of long-term remission of oligo/polyarticular juvenile idiopathic arthritis with S100A12 and vascular endothelial growth factor.
Yamasaki Y; Takei S; Imanaka H; Nerome Y; Kubota T; Nonaka Y; Akaike H; Takezaki T; Kawano Y
Mod Rheumatol; 2016 Jul; 26(4):551-6. PubMed ID: 26474088
[TBL] [Abstract][Full Text] [Related]
17. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab.
Nordal HH; Brun JG; Hordvik M; Eidsheim M; Jonsson R; Halse AK
Scand J Rheumatol; 2016 Jul; 45(4):274-81. PubMed ID: 26767827
[TBL] [Abstract][Full Text] [Related]
18. Patient-Reported Outcomes Among Patients Ages Two to Seventeen Years With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: Two-Year Results From an International Phase III Study.
Ruperto N; Lovell DJ; Berman A; Ávila-Zapata F; Horneff G; Alessio M; Becker ML; Belot A; Burgos-Vargas R; Gamir ML; Goldenstein-Schainberg C; Scheibel IM; Terreri MT; Zemel L; Zhuo J; Askelson M; Wong R; Martini A; Brunner HI;
Arthritis Care Res (Hoboken); 2023 Aug; 75(8):1804-1814. PubMed ID: 36710243
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Maintenance of Clinical Responses by Individual Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Abatacept.
Brunner HI; Tzaribachev N; Louw I; Calvo Penades I; Avila-Zapata F; Horneff G; Foeldvari I; Kingsbury DJ; Paz Gastanaga ME; Wouters C; Breedt J; Wong R; Askelson M; Zhuo J; Martini A; Lovell DJ; Ruperto N;
Arthritis Care Res (Hoboken); 2023 Nov; 75(11):2259-2266. PubMed ID: 37221146
[TBL] [Abstract][Full Text] [Related]
20. Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept.
Brunner HI; Tzaribachev N; Cornejo GV; Joos R; Gervais E; Cimaz R; Calvo Penadés I; Cuttica R; Lutz T; Quartier P; Gandhi Y; Nys M; Wong R; Martini A; Lovell DJ; Ruperto N;
Pediatr Rheumatol Online J; 2020 Feb; 18(1):19. PubMed ID: 32087715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
